KRAS crowding continues
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Affimed looks to reverse a share price collapse
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.
Christmas holiday round-up
As the biotech markets turned bullish the sector’s ups and downs continued.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
Astra scoops JP Morgan
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
Interview – Kura’s combo test nears
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?
